Literature DB >> 12151112

New horizons in the development of antiepileptic drugs.

Wolfgang Löscher1, Dieter Schmidt.   

Abstract

Significant advances have been made in the treatment of epilepsy over the past decades. However, despite the development of various novel antiepileptic drugs, about one third of patients with epilepsy is resistant to current pharmacotherapies. Even in patients in whom pharmacotherapy is efficacious, current antiepileptic drugs do not seem to affect the progression or underlying natural history of epilepsy. Furthermore, there is currently no drug available which prevents the development of epilepsy, e.g. after head trauma. Thus, there are at least three important goals for the future. (1) Better understanding of processes leading to epilepsy, thus allowing to create therapies aimed at the prevention of epilepsy in patients at risk; (2) improved understanding of biological mechanisms of pharmacoresistance, allowing to develop drugs for reversal or prevention of resistance; and (3) development of disease-modifying therapies, inhibiting the progression of epilepsy. The ultimate goal would be a drug combining these three properties, thus resulting in a complete cure for epilepsy. In this review, the current status of antiepileptic therapies is critically assessed, and innovative approaches for future therapies are highlighted.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12151112     DOI: 10.1016/s0920-1211(02)00063-3

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  20 in total

1.  Conventional anticonvulsant drugs in the guinea-pig kindling model of partial seizures: effects of repeated administration.

Authors:  Trevor H Gilbert; G Campbell Teskey
Journal:  Exp Brain Res       Date:  2007-01-26       Impact factor: 1.972

2.  Nontraditional epilepsy treatment approaches.

Authors:  Michael A Rogawski; Gregory L Holmes
Journal:  Neurotherapeutics       Date:  2009-04       Impact factor: 7.620

3.  Post-traumatic seizure susceptibility is attenuated by hypothermia therapy.

Authors:  Coleen M Atkins; Jessie S Truettner; George Lotocki; Juliana Sanchez-Molano; Yuan Kang; Ofelia F Alonso; Thomas J Sick; W Dalton Dietrich; Helen M Bramlett
Journal:  Eur J Neurosci       Date:  2010-10-29       Impact factor: 3.386

4.  Influences of "spasmolytic powder" on pgp expression of Coriaria Lactone-kindling drug-resistant epileptic rat model.

Authors:  Lei Chen; Peimin Feng; Yaohua Li; Dong Zhou
Journal:  J Mol Neurosci       Date:  2012-12-20       Impact factor: 3.444

5.  Synergistic anticonvulsant effects of pregabalin and amlodipine on acute seizure model of epilepsy in mice.

Authors:  Itefaq Hussain Qureshi; Azra Riaz; Rafeeq Alam Khan; Afaq Ahmed Siddiqui
Journal:  Metab Brain Dis       Date:  2017-03-09       Impact factor: 3.584

6.  Post-traumatic seizures exacerbate histopathological damage after fluid-percussion brain injury.

Authors:  Ying-hui Bao; Helen M Bramlett; Coleen M Atkins; Jessie S Truettner; George Lotocki; Ofelia F Alonso; W Dalton Dietrich
Journal:  J Neurotrauma       Date:  2010-10-12       Impact factor: 5.269

Review 7.  Animal models of limbic epilepsies: what can they tell us?

Authors:  Douglas A Coulter; Dan C McIntyre; Wolfgang Löscher
Journal:  Brain Pathol       Date:  2002-04       Impact factor: 6.508

Review 8.  The Role of Wnt/β-Catenin Signaling Pathway in Disrupted Hippocampal Neurogenesis of Temporal Lobe Epilepsy: A Potential Therapeutic Target?

Authors:  Cheng Huang; Xiang-Hui Fu; Dong Zhou; Jin-Mei Li
Journal:  Neurochem Res       Date:  2015-05-27       Impact factor: 3.996

9.  DNA topoisomerase I inhibitors ameliorate seizure-like behaviors and paralysis in a Drosophila model of epilepsy.

Authors:  J Song; L Parker; L Hormozi; M A Tanouye
Journal:  Neuroscience       Date:  2008-07-23       Impact factor: 3.590

10.  Post-traumatic epilepsy following fluid percussion injury in the rat.

Authors:  Raimondo D'Ambrosio; Jared P Fairbanks; Jason S Fender; Donald E Born; Dana L Doyle; John W Miller
Journal:  Brain       Date:  2003-11-07       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.